Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Head and Neck Squamous Cell Carcinoma: early-phase trial registry
71 of 125 indexed Head and Neck Squamous Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #95 of 28,707 conditions by registered trial count.
125 US clinical trials · 71 currently recruiting · #95 of 28,707 conditions by registered trial count
Head and Neck Squamous Cell Carcinoma: 125 US clinical trials tracked, 71 recruiting.
Head and Neck Squamous Cell Carcinoma is the subject of 125 registered US clinical trials on ClinicalTrials.gov, 71 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 111 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 5 of these trials.
Enrollment posture brief
Registry condition head-and-neck-squamous-cell-carcinoma
OPEN 71 | RECR 57% | LATE 4 | EARLY 111 | RANK #95 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Survivorship (57% recruiting · 37 trials)
Head and Neck Squamous Cell Carcinoma lists 71 open slots (57% of 125 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Head and Neck Squamous Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Head and Neck Squamous Cell Carcinoma is recruiting above its size-band peers.
71 of 125 indexed trials (56.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Head and Neck Squamous Cell Carcinoma trials is spread across many organizations.
AstraZeneca accounts for 5 of 125 trials (4%). 89 distinct sponsors appear on at least one study for this condition label.
-
Most Head and Neck Squamous Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 61 among the 125 trials that report a genuine target (sentinel values excluded). 84 of those (67.2%) plan for fewer than 100 participants.
-
Head and Neck Squamous Cell Carcinoma research is mostly interventional.
122 interventional and 3 observational studies make up this index (97.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
125 total, page 3 of 3
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Kathryn Gold
NCT03498378
Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04848116
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer
Providence Health & Services
NCT03247712
Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients
Trisha Wise-Draper
NCT04414540
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
Megan Daly, MD
NCT03474497
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
Dan Zandberg
NCT04369937
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience
NCT03552718
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
TILT Biotherapeutics
NCT05222932
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
American College of Radiology
NCT05540899
Phase Ib of L-NMMA and Pembrolizumab
The Methodist Hospital Research Institute
NCT03236935
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
NCT02432963
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
NCT06870487
Use of a Non-ICU Specialty Ward For Immediate Post-operative Management of Head and Neck Free Flaps
University of California, Davis
NCT03340038
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01696955
Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers
Tvardi Therapeutics, Incorporated
NCT03195699
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
University of Southern California
NCT03049618
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
OncoNano Medicine
NCT03735680
Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma
Baylor College of Medicine
NCT02949700
Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03878979
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
National Cancer Institute (NCI)
NCT01711541
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
AstraZeneca
NCT03022409
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
NCT04452214
PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
Presage Biosciences
NCT06062602
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
Pure Biologics S.A.
NCT06273852
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
NCT03993353
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 68 |
| Phase 2 | 43 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Head and Neck Squamous Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Head and Neck Squamous Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Head and Neck Squamous Cell Carcinoma page
125 registered trials, 71 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 71 Head and Neck Squamous Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Head and Neck Squamous Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Head and Neck Squamous Cell Carcinoma condition card totals 125 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.